CoChat
Sign Up
Cited by 169Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors

Giugliano, D., Quatraro, A., Consoli, G., Minei, A., Ceriello, A., De Rosa, N., D'Onofrio, F.·1993·European Journal of Clinical Pharmacology
DOI 10.1007/bf00315466
Open this paper in CoChat — free account

Abstract

The efficacy and safety of metformin in the treatment of obese, non-insulin-dependent, diabetic subjects poorly controlled by insulin after secondary failure to respond to sulphonylureas has been investigated. Fifty insulin-treated, obese diabetics participated in this prospective, randomised double-blind six-month trial. After a four-week run-in period, during which all patients were given placebo (single-blind), patients were randomly assigned to continue to receive placebo or to active treatment with metformin. At six months, there was a relevant and significant improvement in glycaemic control in diabetics receiving the combined insulin-metformin treatment (decrease in glucose -4.1 mmol.l-1; glycosylated haemoglobin A1 decrease -1.84%). No significant changes were seen in diabetics receiving insulin and placebo. There was a significant decrease in blood lipids (trygliceride and cholesterol), an increase in HDL-cholesterol and a reduction in blood pressure in diabetics taking metformin. These positive findings were most marked in the 14 diabetics who experienced a good response to metformin (glucose profile < 10 mmol.l-1), and were less marked but still significant in the remaining 13 diabetics, whose response to therapy was not so good (glucose profile > 10 mmol.l-1). The fasting insulin level was significantly lower after six months of combined insulin-metformin treatment as shown by a 25% reduction in the daily dose of insulin (-21.6 U/day). Metformin was well tolerated by all diabetics.(ABSTRACT TRUNCATED AT 250 WORDS)

Integrity signals

Registry

Crossref · 10.1007/bf00315466

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metformin added to insulin-based regimens improves glycemic control, limits changes in body weight, reduces hypoglycemia incidence, and reduces insulin requirements, allowing a 15-25% reduction in total insulin dosage.

    “Metformin as added to insulin-based regimens has been shown to improve glycemic control, limit changes in body weight, reduce hypoglycemia incidence, and to reduce insulin requirements (sparing effect), allowing a 15–25% reduction in total insulin dosage [28,29].”

    From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [28]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Giugliano, D., Quatraro, A., Consoli, G., Minei, A., Ceriello, A., De Rosa, N., & D'Onofrio, F.
Affiliations
  • University of Naples Federico II (IT)
  • University of Udine (IT)
ORCID
Venue
European Journal of Clinical Pharmacology
Publisher
Springer Science and Business Media LLC
Published
1993-03
Volume
44
Issue
2
Pages
107-112
ISSN
  • 0031-6970 (ISSN-L)
  • 1432-1041
DOI
10.1007/bf00315466
OpenAlex
W1979110885
Cited by
169
References
31
Citations by year
2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 2 · 2013: 5 · 2012: 4
FWCI
3.89
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System (University of Udine) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
metformin, insulin-treated diabetes, obesity, glycemic control, glycosylated haemoglobin, serum lipids, HDL cholesterol, triglycerides, blood pressure, insulin dose reduction, fasting insulin, drug safety
MeSH terms
Blood Glucose, Blood Pressure, C-Peptide, Diabetes Mellitus, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Glycated Hemoglobin, Homeostasis, Humans, Islets of Langerhans, Lipids, Male, Metformin, Middle Aged, Obesity, Prospective Studies, Risk Factors, Single-Blind Method

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review